PPARGC1A and metabolic disease: Lipid and glucose metabolism from muscle can be regulated by stimulation of the AMPK-SIRT1-PGC-1α signaling pathway, and the activities of AMPK, SIRT1, and PGC-1α can be inhibited by obesity and other metabolic diseases, which impair lipid and glucose metabolism in skeletal muscle [36,37,38,39].